Related papers: SFNet: A Spatial-Frequency Domain Deep Learning Ne…
Alzheimer's Disease (AD) is the world leading cause of dementia, a progressively impairing condition leading to high hospitalization rates and mortality. To optimize the diagnostic process, numerous efforts have been directed towards the…
Existing research has shown the potential of classifying Alzheimers Disease (AD) from eye-tracking (ET) data with classifiers that rely on task-specific engineered features. In this paper, we investigate whether we can improve on existing…
Detection of Alzheimer's Disease (AD) from neuroimaging data such as MRI through machine learning have been a subject of intense research in recent years. Recent success of deep learning in computer vision have progressed such research…
Accurate and early diagnosis of Alzheimer's disease (AD) is critical for effective intervention and requires integrating complementary information from multimodal neuroimaging data. However, conventional fusion approaches often rely on…
Alzheimer's disease (AD) is the most common form of dementia, which causes problems with memory, thinking and behavior. Growing evidence has shown that the brain connectivity network experiences alterations for such a complex disease.…
Alzheimer's disease is an untreatable, progressive brain disorder that slowly robs people of their memory, thinking abilities, and ultimately their capacity to complete even the most basic tasks. Among older adults, it is the most frequent…
FDG-PET reveals altered brain metabolism in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Some biomarkers derived from FDG-PET by computer-aided-diagnosis (CAD) technologies have been proved that they can…
Alzheimer's Disease (AD) is a progressive disease preceded by Mild Cognitive Impairment (MCI). Early detection of AD is crucial for making treatment decisions. However, most of the literature on computer-assisted detection of AD focuses on…
Longitudinal neuroimaging is essential for modeling disease progression in Alzheimer's disease (AD), yet irregular sampling and missing visits pose substantial challenges for learning reliable temporal representations. To address this…
Alzheimer's disease is a degenerative brain disease. Being the primary cause of Dementia in adults and progressively destroys brain memory. Though Alzheimer's disease does not have a cure currently, diagnosing it at an earlier stage will…
Imaging-based early diagnosis of Alzheimer Disease (AD) has become an effective approach, especially by using nuclear medicine imaging techniques such as Positron Emission Topography (PET). In various literature it has been found that PET…
Alzheimer's disease (AD) progresses through distinct stages, from early mild cognitive impairment (EMCI) to late mild cognitive impairment (LMCI) and eventually to AD. Accurate identification of these stages, especially distinguishing LMCI…
This study is based on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and aims to explore early detection and disease progression in Alzheimer's disease (AD). We employ innovative data preprocessing strategies, including the…
Alzheimer's disease (AD) confirmation often relies on positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis, which are costly and invasive. Consequently, structural MRI biomarkers such as cortical thickness (CT) are…
Deep learning has shown significant potential in diagnosing neurodegenerative diseases from MRI data. However, most existing methods rely heavily on large volumes of labeled data and often yield representations that lack interpretability.…
{Introduction: } Dementia is a neurological disorder associated with aging that can cause a loss of cognitive functions, impacting daily life. Alzheimer's disease (AD) is the most common cause of dementia, accounting for 50--70\% of cases,…
Background: Although convolutional neural networks (CNN) achieve high diagnostic accuracy for detecting Alzheimer's disease (AD) dementia based on magnetic resonance imaging (MRI) scans, they are not yet applied in clinical routine. One…
Neurodegeneration as measured through magnetic resonance imaging (MRI) is recognized as a potential biomarker for diagnosing Alzheimer's disease (AD), but is generally considered less specific than amyloid or tau based biomarkers. Due to a…
Subjective cognitive decline (SCD) is a preclinical stage of Alzheimer's disease (AD) which occurs even before mild cognitive impairment (MCI). Progressive SCD will convert to MCI with the potential of further evolving to AD. Therefore,…
Deep learning methods based on Convolutional Neural Networks (CNNs) have shown great potential to improve early and accurate diagnosis of Alzheimer's disease (AD) dementia based on imaging data. However, these methods have yet to be widely…